Saroj Kumar Mishra
A 50% efficacy in COVID-19, vaccine, is not a benchmark, it should be at least 70%. For impressive prevention of coronavirus pandemic, efficacy is most important.
A vaccine should have Safety, immunogenicity, efficacy. Drugs have side effects. Many pharmaceutical companies are in the race to develop Covid-19 vaccines. Their share prices are favourably impacted, company insiders should not be allowed insider trading,phase-3 trials results have not come out so far.
Vaccine development will be a legitimate opportunity, retail investors, mutual fund managers need to concentrate on the benchmark of the vaccine.
